Trevena Reports First Quarter 2024 Results and Provides Business Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile

Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024